Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Interest & Investment Income (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Interest & Investment Income data on record, last reported at $21.3 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income changed 0.32% year-over-year to $21.3 million; the TTM value through Dec 2025 reached $90.7 million, up 4.39%, while the annual FY2025 figure was $90.7 million, 4.39% up from the prior year.
  • Interest & Investment Income reached $21.3 million in Q4 2025 per RVMD's latest filing, down from $70.3 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $70.3 million in Q3 2025 and bottomed at -$25.8 million in Q2 2025.
  • Average Interest & Investment Income over 5 years is $11.8 million, with a median of $8.8 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: surged 2237.42% in 2023, then plummeted 220.18% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $237000.0 in 2021, then soared by 2042.62% to $5.1 million in 2022, then soared by 273.71% to $19.0 million in 2023, then grew by 11.85% to $21.2 million in 2024, then grew by 0.32% to $21.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $21.3 million in Q4 2025, $70.3 million in Q3 2025, and -$25.8 million in Q2 2025.